Invention Grant
- Patent Title: Replication-enhanced oncolytic adenoviruses
-
Application No.: US17091549Application Date: 2020-11-06
-
Publication No.: US11951141B2Publication Date: 2024-04-09
- Inventor: Mark J. Cantwell , Amer A. Beg
- Applicant: MEMGEN, Inc. , H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Applicant Address: US TX Houston
- Assignee: MEMGEN, INC.,H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Current Assignee: MEMGEN, INC.,H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
- Current Assignee Address: US TX Houston; US FL Tampa
- Agency: Jackson Walker LLP
- Agent Leisa Talbert Peschel
- Main IPC: A61K35/761
- IPC: A61K35/761 ; A61P35/00 ; C12N7/00 ; C12N15/113 ; C12N15/12 ; C12N15/22
Abstract:
Disclosed are replication-enhanced oncolytic adenoviruses. These oncolytic adenoviruses have tumor-specific replication capable of enhanced tumor oncolysis and enhanced therapeutic transgene expression. Also disclosed are methods comprising administering a replication-enhanced oncolytic adenovirus for patients suffering from a cancer.
Public/Granted literature
- US20210128653A1 REPLICATION-ENHANCED ONCOLYTIC ADENOVIRUSES Public/Granted day:2021-05-06
Information query
